Volume 121, Issue 1 , Pages 30-37.e6, January 2008
Molecular phenotyping of severe asthma using pattern recognition of bronchoalveolar lavage–derived cytokines
Background
Asthma is a heterogeneous clinical disorder. Methods for objective identification of disease subtypes will focus on clinical interventions and help identify causative pathways. Few studies have explored phenotypes at a molecular level.
Objective
We sought to discriminate asthma phenotypes on the basis of cytokine profiles in bronchoalveolar lavage (BAL) samples from patients with mild-moderate and severe asthma.
Methods
Twenty-five cytokines were measured in BAL samples of 84 patients (41 severe, 43 mild-moderate) using bead-based multiplex immunoassays. The normalized data were subjected to statistical and informatics analysis.
Results
Four groups of asthmatic profiles could be identified on the basis of unsupervised analysis (hierarchical clustering) that were independent of treatment. One group, enriched in patients with severe asthma, showed differences in BAL cellular content, reductions in baseline pulmonary function, and enhanced response to methacholine provocation. Ten cytokines were identified that accurately predicted this group. Classification methods for predicting methacholine sensitivity were developed. The best model analysis predicted hyperresponders with 88% accuracy in 10 trials by using a 10-fold cross-validation. The cytokines that contributed to this model were IL-2, IL-4, and IL-5. On the basis of this classifier, 3 distinct hyperresponder classes were identified that varied in BAL eosinophil count and PC20 methacholine.
Conclusion
Cytokine expression patterns in BAL can be used to identify distinct types of asthma and identify distinct subsets of methacholine hyperresponders. Further biomarker discovery in BAL may be informative.
Key words: Asthma, inflammation, cytokines, phenotypes, ELISA, hierarchical clustering, bioinformatics, class discovery
Abbreviations used: ATS, American Thoracic Society, BAL, Bronchoalveolar lavage, FVC, Forced vital capacity, IL-1Ra, IL-1 receptor antagonist, LR, Low responder, MCP, Monocyte chemoattractant protein, MIP, Macrophage inflammatory protein, MOP, Manual of procedures, SARP, Severe Asthma Research Program
Supported by National Institutes of Health grant AI062885 (A.R.B.), a National Institute of Environmental Health Sciences Pilot Project (A.R.B.), National Heart, Lung, and Blood Institute contract BAA-HL-02-04 (A. Kurosky), HL69130 US Severe Asthma Research Program (W.J.C.), and the Integrated Health Science Facility Core P30 ES06676 (to J. Halpert, UTMB).
Disclosure of potential conflict of interest: W. W. Busse has consulting arrangements with Genentech/Novartis, Isis, GlaxoSmithKline, Altanta, Wyeth, Pfizer, Dynavax, Centocor, Johnson and Johnson, Hoffman LaRoche, Alza CV Therapeutics, Takeda, Abbott, and Millenium; has received grant support from Novartis, Dynavax, Wyeth, Centocor, GlaxoSmithKline, Medicinova, Sanofi-Aventis, Dey, Pfizer, Astellas Pharma, Inflazyme, and Biowa; and is on the speakers' bureau for Novartis, Merck, and AstraZeneca. W. J. Calhoun has received grant support from Sepracor. The rest of the authors have declared that they have no conflict of interest.
PII: S0091-6749(07)01960-4
doi:10.1016/j.jaci.2007.10.015
© 2008 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.
Volume 121, Issue 1 , Pages 30-37.e6, January 2008
